The risk of both non-Hodgkin’s lymphoma and Hodgkin’s lymphoma remains markedly increased in People Living with Human Immunodeficiency Virus (PLWH), including in the era of effective antiretroviral therapy. Many studies have excluded PLWH, including those who don’t meet restrictive absolute CD4 counts or HIV load standards, or have compromised organ function and/or impaired performed status, which limits information regarding safety and efficacy of both established and novel potentially curative therapies in PLWH.
Leadership
Chair
Vice Chair
International Vice Chair
The overall goals of the Hematologic Malignancy Working Group include to:
- Incorporate new targeted therapies into the treatment of lymphoma
- Evaluate the efficacy and safety of novel immunotherapeutic strategies
- Evaluate therapeutic strategies for rare lymphoma subtypes associated with poor prognosis that disproportionately effect PLWH
- Leverage experience in treating PLWH and hematologic malignancies to provide insights into pathogenesis/prognosis of these malignancies or HIV pathogenesis.
Several trials addressing these goals are currently in progress and/or are in development by the HMWG. Please check out our Current Studies.